Pharmaceutical - Daiichi Sankyo, Licensing

Filter

Current filters:

Daiichi SankyoLicensing

Popular Filters

Daiichi Sankyo and Charleston Laboratories sign collaboration deal worth up to $650 million

Daiichi Sankyo and Charleston Laboratories sign collaboration deal worth up to $650 million

07-08-2014

Japanese drug major Daiichi Sankyo and privately-held Charleston Laboratories, through its wholly owned…

AnalgesiaCharleston LaboratoriesDaiichi SankyoHydrocodone combination productsJapanLicensingMorphinansPharmaceuticalUSA

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

10-07-2014

USA-based Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Japanese…

andexanet alfaCardio-vascularDaiichi SankyoedoxabanJapanLicensingPharmaceuticalPortola PharmaceuticalsResearchSavaysaUSA

Dainippon Sumitomo and Daiichi Sankyo cooperate on lurasidone in South America

Dainippon Sumitomo and Daiichi Sankyo cooperate on lurasidone in South America

28-05-2014

Japanese drug majors Dainippon Sumitomo Pharma and Daiichi Sankyo have entered into a license agreement…

ArgentinaBrazilDaiichi SankyoDainippon Sumitomo PharmaLicensinglurasidoneNeurologicalPharmaceuticalSouth AmericaVenezuela

Astellas and Daiichi Sankyo share 400,000 compounds in research agreement

Astellas and Daiichi Sankyo share 400,000 compounds in research agreement

19-03-2014

Japanese drug majors Astellas Pharma and Daiichi Sankyo will form a compound library sharing partnership…

Astellas PharmaDaiichi SankyoJapanLicensingPharmaceuticalResearch

Daiichi Sankyo and UMN Pharma collaborate over norovirus vaccine

Daiichi Sankyo and UMN Pharma collaborate over norovirus vaccine

14-02-2014

Japanese drug companies Daiichi Sankyo and UMN Pharma have signed a collaborative research agreement…

Daiichi SankyoJapanLicensingPharmaceuticalResearchVaccines

Kowa and Daiichi Sankyo to end joint marketing partnership in Japan

07-04-2013

Privately-held Japanese drugmaker Kowa and pharma major Daiichi Sankyo (TYO: 4568) say they will be ending…

Asia-PacificCardio-vascularDaiichi SankyoKowa PharmaceuticalsLicensingLivaloMarkets & MarketingOlmetecPharmaceutical

Daiichi Sankyo returns rights to ArQule for global AKT program

03-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has returned worldwide rights for the development and…

ARQ 092ARQ 197ArQuleDaiichi SankyoLicensingOncologyPharmaceuticalResearchtivantinib

Daiichi Sankyo to license ARQ 092 from ArQule, under joint AKIP research collaboration

11-11-2011

Japanese drug major Daiichi Sankyo (TSE 4568) says it has executed a license agreement with USA-based…

ArQuleDaiichi SankyoLicensingOncologyPharmaceuticalResearch

Back to top